Smith+Nephew introduces the RENASYS™ EDGE Negative Pressure Wound Therapy System – an exciting new option in home-based care for patients living with chronic wounds

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, is pleased to announce the launch of its RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System in the US as a patient-centric option for treating chronic wounds. The system is lightweight and compact allowing it to be easily carried or worn,1 it features a discreet canister, and operates quietly so as not to draw attention or disturb the patients’ daily activities.1

It is estimated that the annual financial burden of chronic wounds in the US is $33 billion,2 and affecting some 8.2 million people.*3 The RENASYS EDGE System is designed for patients suffering from these wounds and living at home. Chronic wounds, including ulcers, have a huge impact on a patient’s life beyond just the pain and discomfort, with 68% often becoming self-conscious of their wound and many becoming isolated.4 The need to carry a bulky, noisy medical device that draws attention to their condition only increases this discomfort.

Smith+Nephew is also announcing two new national distribution partners for the RENASYS EDGE System - SunMED Medical Solutions and First Nation Group. These new partnerships will enable Smith+Nephew to introduce this new, innovative technology to more patients on a national level and support its growing negative pressure wound therapy business.

“When designing the RENASYS EDGE System we kept patients and their needs in the forefront of our minds. It’s the very definition of our purpose – Life Unlimited - allowing patients to continue with their daily lives while receiving prescribed negative pressure wound therapy,” stated Laura Ackerman, Vice President and General Manager, NPWT at Smith+Nephew. “And now with SunMED in the commercial healthcare market and First Nation Group supporting our veterans, RENASYS EDGE will be able to create a lasting impact on the way patients experience the benefit of negative pressure wound therapy in the comfort of their home.”

Burt Thomas, a RENASYS EDGE patient explained his experience with the system by stating, “I was not hindered by it at all. I was able to go on outings, play games, and was actually able to do a lot of day-to-day activities. I hope other people can benefit like I did.” 

For clinicians, the RENASYS EDGE system is intuitive and easy-to-use.5 Its user-friendly interface gives step-by-step guidance on therapy application,5 and technical support is just one click away during set up with the near field communication feature on the system. Additionally, Smith+Nephew provides 24-hour customer support for patients and a clinical hotline.   

Clinicians wanting to learn more about how the RENASYS EDGE System can support their clinical practice and benefit patients can visit the RENASYS EDGE page on Smith+Nephew’s website, or contact their local Smith+Nephew sales representative. For information on our national distribution partners please visit their websites: SunMED Medical Solutions and First Nation Group.

- ends -


David Snyder+1 (978) 749-1440

* based on Medicare beneficiaries


  1. Smith+Nephew 2022. Internal Report. EO.AWM.PCS270.003.v1.
  2. Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons NB. Burden of diabetic foot ulcers for Medicare and private insurers. Diabetes Care. 2014 Mar;37(3):651-8. Numbers are rounded where appropriate.
  3. Sen CK. Human wounds and its burden: An updated compendium of estimates. Advances in Wound Care, 2019; 8(2):39-48
  4. Phillips T, StantonB, Provan A, Lew R. A study of the impact of leg ulcers on quality of life: financial, social, and psychologic implications. J Am Acad Dermatol. 1994;31(1):49–53
  5. Smith and Nephew 2022. RENASYS EDGE System Human Factors Summative Report Summary. Internal Report. CSD.AWM.22.071.

For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product’s applicable Instructions for Use (IFU) prior to use. 

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.5 billion in 2023. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit and follow us on X, LinkedIn, Instagram or Facebook.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www., for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.

Primary Logo

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.